Equity
€502,844 ▲ 11.9%
VDS PHARMA has made a profit in every financial year since 2016.
VDS PHARMA
Overview
Lifetime
10 annual accounts with figures on one time axispeak €139,425 (2018)
€106,828▲ 194%
peak €97,686 (2022)
€74,668▲ 333%
peak €502,844 (2025)
€502,844▲ 11.9%
€318,876▼ 17.0%
peak 0 FTE (2023)
0 FTE
Board1 name since 2015
1 directorVANDERSTEEN Zoë
Documentsfilings and deeds
14-04-202616 days before the deadline
2025abbreviated format
Gross margin from €36,307 to €106,828Result from €17,244 to €74,668Dividend €21,176Debts from €384,409 to €318,876Cash from €7,981 to €23,878
Key points
from the 2025 annual accountsResult
€74,668 ▲ 333%
The result rose in 2025 from €17,244 to €74,668.
Filings
10 annual accounts since 2016
The last five annual accounts were filed 1 to 37 days before the end of the period.
Financial institution: outside the modelBankruptcy probability: sector outside the model
Checked score
Outside the general model
Model not applicable to financial institutions
The Checked score measures liquidity, leverage and margins against the norms for trading and manufacturing companies. A bank, insurer or financial holding has a very different balance sheet. Those ratios and the score mean nothing here. So there is no financial strength either.
Bankruptcy probability within 12 months
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
1 signal, which does not raise the risk
1 signal.
neutral
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 14-04-2026, 16 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
16 days early
2024
19 days early
2023
5 days early
2022
37 days early
2021
1 day early
2020
on the day
2019
20 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 14 days before the deadline. In the sector (NACE 64), the median for financial year 2024 was 14 days before the deadline, and 28% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-09-2026 is due by 30-04-2027. Nothing is late today. The company usually files around 14 April (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-09-2026 year end08-11-2026 today30-04-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0597740922
Resignation: VANDERSTEEN Zoë (director)
Reappointment: VANDERSTEEN Zoë (director) · Gazette deed
Registered office moved within Sint-Pieters-Leeuw
New registered office: Zuundallaan 22, 1600 Sint-Pieters-Leeuw · Previous registered office: Drogenbosstraat 25 bus 3, 1600 Sint-Pieters-Leeuw · General meeting of 06-11-2018 · Gazette deed
Incorporation
published on 10-02-2015 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| VDS PHARMA Sint-Pieters-Leeuw | €0.8m | €106,828 | 61.2% | 0 |
| Julie Decroos Glabbeek | €1.0m | €110,189 | 39.2% | 0 |
| EGGEVOLT MANAGEMENT Wommelgem | €0.7m | €106,827 | 16.1% | 0 |
| GDRCH Tournai | €0.9m | €122,903 | 54.7% | 0 |
| Grevant Ronse | €0.8m | €135,120 | 2.2% | 0 |
| PROPERTY CUBE Kortrijk | €0.7m | €84,660 | 67.7% | 0 |
| G & G Damme | €1.1m | €120,141 | 58.7% | 0 |
These companies have the same main activity as VDS PHARMA: activities of holding companies (NACE 64210). They are comparable in size and age: total assets between €728,000 and €1.1m, founded between 2013 and 2016.
Official details
Source: KBO- Status
- Active since 06-02-2015Normal situation
- Activity
- Activities of holding companiesNACE 64210and 2 others
- Establishment unit
- 2.239.917.7631600 Sint-Pieters-Leeuw, since 06-02-2015
- Financial year end
- 30 September
- Peppol
- Reachable since 25-09-2025
Annual accounts to 30-09-2025
- €74,668▲ 333%
- €502,844▲ 11.9%
- €821,719▼ 1.4%
- Filing
- Filed on 14-04-2026, 16 days before the end of the filing period
Insights on VDS PHARMA
VDS PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €59,025 in 2016 to €106,828 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
abbreviated format, filed on 14-04-2026, 16 days before the deadline€502,844
▲ 11.9%
€821,719
▼ 1.4%
€74,668
▲ 333%
61.2%
▲ 7.3 percentage points
14.8%
▲ 11.0 percentage points
9.1%
▲ 7.0 percentage points
Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Balance sheet
balance sheet total €821,719 on 30-09-2025What the company ownsHow it is paid for
in euro
in euro
Position in the sector
61.2%
Higher than 60% of 6,708 companies in 2025.
9.1%
Higher than 67% of 6,673 companies in 2025.
VDS PHARMA
Middle half of the sector
80% of the sector
Abbreviated accounts in financial services (NACE 64)
Net result: middle half · Equity: middle half · Balance sheet total: middle half · Staff: middle half
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | |||||||||||
20/58 |
821,719 | 833,761 | 890,532 | 852,931 | 666,748 | 619,009 | 621,018 | 612,309 | 611,751 | 600,385 | |
21/28 |
715,971 | 715,971 | 715,971 | 715,971 | 571,971 | 571,971 | 577,777 | 581,901 | 586,025 | 590,149 | |
22/27 |
- | - | - | - | - | 0 | 1,375 | 5,499 | 9,623 | 13,747 | |
28 |
715,971 | 715,971 | 715,971 | 715,971 | 571,971 | 571,971 | 576,402 | 576,402 | 576,402 | 576,402 | |
29/58 |
105,749 | 117,790 | 174,561 | 136,961 | 94,777 | 47,038 | 43,241 | 30,408 | 25,726 | 10,236 | |
40/41 |
81,871 | 109,809 | 162,957 | 125,962 | 83,388 | 37,065 | 25,708 | 98 | 12,557 | 48 | |
40 |
80,000 | 93,300 | 148,800 | 100,598 | 70,798 | 36,300 | 25,583 | - | 12,130 | - | |
41 |
1,871 | 16,509 | 14,157 | 25,363 | 12,590 | 765 | 125 | 98 | 427 | 48 | |
54/58 |
23,878 | 7,981 | 11,604 | 10,999 | 11,389 | 9,734 | 17,533 | 30,310 | 13,169 | 10,188 | |
490/1 |
- | - | - | - | 0 | 239 | - | - | - | - | |
| Balance sheet: equity and liabilities | |||||||||||
10/49 |
821,719 | 833,761 | 890,532 | 852,931 | 666,748 | 619,009 | 621,018 | 612,309 | 611,751 | 600,385 | |
10/15 |
502,844 | 449,351 | 447,107 | 373,328 | 283,242 | 210,428 | 157,471 | 112,279 | 33,840 | 32,360 | |
10/11 |
18,600 | 18,600 | 18,600 | 18,600 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | |
100 |
- | - | - | - | - | - | 18,600 | 18,600 | 18,600 | 18,600 | |
101 |
- | - | - | - | - | - | 12,400 | 12,400 | 12,400 | 12,400 | |
13 |
484,244 | 430,751 | 428,507 | 354,728 | 277,042 | 204,228 | 151,271 | 106,079 | 27,640 | 26,160 | |
130/1 |
- | 0 | 1,860 | 1,860 | 1,860 | 1,860 | - | - | - | - | |
130 |
- | - | - | - | - | - | 1,860 | 1,860 | 1,860 | 1,308 | |
1311 |
- | 0 | 1,860 | 1,860 | 1,860 | 1,860 | - | - | - | - | |
133 |
484,244 | 430,751 | 426,647 | 352,868 | 275,182 | 202,368 | 149,411 | 104,219 | 25,780 | 24,852 | |
14 |
0 | 0 | 0 | 0 | 0 | - | - | - | - | - | |
17/49 |
318,876 | 384,409 | 443,424 | 479,603 | 383,505 | 408,581 | 463,547 | 500,030 | 577,911 | 568,025 | |
17 |
176,678 | 217,417 | 266,285 | 320,609 | 238,007 | 280,871 | 331,835 | 379,976 | 408,049 | 461,244 | |
170/4 |
176,678 | 217,417 | 266,285 | 320,609 | 238,007 | 280,871 | 331,835 | 379,976 | 408,049 | 461,244 | |
42/48 |
142,023 | 166,220 | 176,412 | 156,861 | 143,399 | 125,643 | 130,023 | 119,612 | 168,857 | 105,806 | |
42 |
51,731 | 51,021 | 77,274 | 88,076 | 58,031 | 66,082 | 50,722 | 61,645 | 35,697 | 35,164 | |
43 |
- | - | - | - | - | - | 0 | 13 | - | - | |
430/8 |
- | - | - | - | - | - | 0 | 13 | - | - | |
44 |
2,792 | 6,426 | 641 | 3,256 | 1,151 | 1,269 | 803 | 1,289 | 530 | 432 | |
440/4 |
2,792 | 6,426 | 641 | 3,256 | 1,151 | 1,269 | 803 | 1,289 | 530 | 432 | |
46 |
- | - | - | 0 | 17,200 | - | - | - | - | - | |
45 |
10,488 | 10,386 | 9,531 | 3,840 | 8,616 | 2,858 | 19,191 | 45,772 | 38,237 | 13,394 | |
450/3 |
10,488 | 10,386 | 4,728 | 3,840 | 8,616 | 2,858 | 19,191 | 45,772 | 38,237 | 13,394 | |
454/9 |
- | 0 | 4,803 | - | - | - | - | - | - | - | |
47/48 |
77,011 | 98,388 | 88,965 | 61,689 | 58,402 | 55,434 | 59,308 | 10,892 | 94,393 | 56,816 | |
492/3 |
175 | 772 | 728 | 2,133 | 2,099 | 2,067 | 1,689 | 443 | 1,004 | 975 | |
| Income statement | |||||||||||
76A |
0 | 1,136 | - | 0 | 6,310 | - | - | - | - | - | |
9900 |
106,828 | 36,307 | 127,415 | 128,782 | 101,428 | 79,170 | 74,569 | 139,425 | 84,943 | 59,025 | |
630 |
- | - | - | - | 0 | 1,375 | 4,124 | 4,124 | 4,124 | 6,873 | |
640/8 |
1,219 | 891 | 576 | 558 | 1,039 | 336 | 0 | 567 | 215 | 672 | |
66A |
532 | 1,546 | 204 | 62 | 53 | 256 | 150 | 45 | 53 | - | |
9901 |
105,078 | 33,870 | 126,634 | 128,162 | 100,336 | 77,204 | 70,295 | 134,690 | 80,551 | 51,480 | |
75/76B |
- | 0 | 1,752 | 0 | 0 | - | - | - | 0 | 1 | |
75 |
- | 0 | 1,752 | 0 | 0 | - | - | - | 0 | 1 | |
65/66B |
10,321 | 10,070 | 10,864 | 9,029 | 8,192 | 8,286 | 11,779 | 10,600 | 12,116 | 14,109 | |
65 |
10,321 | 10,070 | 10,864 | 9,029 | 8,192 | 8,286 | 11,779 | 10,600 | 12,116 | 14,109 | |
9903 |
94,756 | 23,800 | 117,522 | 119,133 | 92,144 | 68,917 | 58,516 | 124,090 | 68,436 | 37,372 | |
67/77 |
20,088 | 6,556 | 26,093 | 21,447 | 19,329 | 14,460 | 13,324 | 42,651 | 20,956 | 11,212 | |
9904 |
74,668 | 17,244 | 91,429 | 97,686 | 72,815 | 54,457 | 45,192 | 81,439 | 47,480 | 26,160 | |
9905 |
74,668 | 17,244 | 91,429 | 97,686 | 72,815 | 54,457 | 45,192 | 81,439 | 47,480 | 26,160 | |
| Appropriation of the result | |||||||||||
9906 |
74,668 | 17,244 | 91,429 | 97,686 | 72,815 | 54,457 | 45,192 | 81,439 | 47,480 | 26,160 | |
791/2 |
- | - | 0 | 20,000 | - | - | - | - | - | - | |
691/2 |
53,492 | 2,244 | 73,779 | 97,686 | 72,815 | 52,957 | 45,192 | 78,439 | 1,480 | 26,160 | |
6920 |
- | - | - | - | - | - | - | - | 552 | 1,308 | |
6921 |
53,492 | 2,244 | 73,779 | 97,686 | 72,815 | 52,957 | 45,192 | 78,439 | 928 | 24,852 | |
694/7 |
21,176 | 15,000 | 17,650 | 20,000 | 0 | 1,500 | 0 | 3,000 | 46,000 | - | |
694 |
21,176 | 15,000 | 17,650 | 20,000 | - | - | - | - | 46,000 | - | |
695 |
- | - | - | - | 0 | 1,500 | 0 | 3,000 | - | - | |
| Social balance sheet | |||||||||||
9087 |
0 | 0 | 0 | - | - | - | - | - | - | - | |
| Document | |||||||||||
The notes to these accounts have 13 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 14-04-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-09-2025 | abbreviated format | 14-04-2026 | 2026-00078765 | |
| 30-09-2024 | abbreviated format | 11-04-2025 | 2025-00067910 | |
| 30-09-2023 | abbreviated format | 25-04-2024 | 2024-00069604 | |
| 30-09-2022 | abbreviated format | 24-03-2023 | 2023-00045293 | |
| 30-09-2021 | abbreviated format | 29-04-2022 | 2022-20013146 | |
| 30-09-2020 | abbreviated format | 30-04-2021 | 2021-12000591 | |
| 30-09-2019 | abbreviated format | 10-04-2020 | 2020-08900462 | |
| 30-09-2018 | abbreviated format | 02-04-2019 | 2019-08600017 | |
| 30-09-2017 | abbreviated format | 03-04-2018 | 2018-08100417 | |
| 30-09-2016 | abbreviated format | 31-03-2017 | 2017-07600592 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 144,000 | 0 | -4,432 | 0 | 0 | -0 | 597,022 | ||
| 15,897 | -3,623 | 605 | -390 | 1,655 | -7,799 | -12,777 | 17,140 | 2,981 | - | ||
| 61.2% | 53.9% | 50.2% | 43.8% | 42.5% | 34.0% | 25.4% | 18.3% | 5.5% | 5.4% | ||
| 14.8% | 3.8% | 20.4% | 26.2% | 25.7% | 25.9% | 28.7% | 72.5% | 140.3% | 80.8% | ||
| 9.1% | 2.1% | 10.3% | 11.5% | 10.9% | 8.8% | 7.3% | 13.3% | 7.8% | 4.4% |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Securities and guarantees
on own assets and for others| Item | 30-09-2025 | 30-09-2024 | 30-09-2023 | 30-09-2022 | 30-09-2021 |
|---|---|---|---|---|---|
| Debts secured on the company's own assets | €219,607 | €259,687 | €343,559 | €240,089 | €283,534 |
| Carrying value of the mortgaged assets | - | - | - | €0 | - |
| Carrying value of the other pledged assets | €715,971 | €715,971 | €715,971 | €715,971 | €571,971 |
Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
fixed assets acquired| Item | 30-09-2025 | 30-09-2024 | 30-09-2023 | 30-09-2022 | 30-09-2021 |
|---|---|---|---|---|---|
| Financial fixed assets | - | - | - | €144,000 | - |
| - | - | - | - | €0 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on VDS PHARMA
The operating result for 2025 is 3.1 times that of 2024. It is a recovery after the fall in 2024.
Debt's share of the balance-sheet total falls from 46.1% to 38.8%. Equity is higher and debt is lower.
Board & ownership
Board
1 director, last change in 2024Director (not named in the articles)
since 06-02-2015
term without a fixed end
earlier director, until 01-02-2024
listed in the 2025 annual accounts, filed on 14-04-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each director alonedeed of 01-02-2024
Mandates through the years
1 name, the dashed line is todayVANDERSTEEN Zoë
Director (not named in the articles)
Director (not named in the articles)
BoardEarliermandate already running before its first mention
Mandates as a list
- VANDERSTEEN Zoë
- Director (not named in the articles), from 06-02-2015 to date
- Director, until 01-02-2024
Control
Capital
- Contribution
- €18,600
- Shares
- 100
- Contribution per share
- €186
- Equity per share
- €5,028 in 2025
- Source
- 2025 annual accounts
Articles of association
deed of 01-02-2024 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Friday of March at 19:00
Network & group
Holdings
own accounts to 30-09-2024This companyVDS PHARMA1 holding, 1 country
accounts to 30-09-2024
Belgium 1 Equity Result
- BE Apotheek Vandersteen BVBA €182,100 result €103,285
Source: list of holdings in its own 30-09-2024 accounts. Every holding stands with its own latest accounts.
At the same address
Zuundallaan 22, 1600 Sint-Pieters-Leeuw · 1 other company| BTWE Groep Vandersteen
registered office since 01-12-2019 |
founded in 2019 0737.520.989 |
Holdings and subsidiaries
1 holdingHoldings 1
Share, source and own figures per holding (1)
- APOTHEEK VANDERSTEENsubsidiaryEquity €182,100 Profit of €103,285 in 2025 (profit of €80,606 in 2024) Checked score 87Sourceown accounts 30-09-2024100%
Holdings through the years 2016 to 2024
| Name | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| APOTHEEK VANDERSTEEN | 80% | 100% | |||||||
Source: list of holdings in its own accounts
Board mandates elsewhere
1 board mandateBoard mandates of VDS PHARMAVDS PHARMA sits on their board1
Connections & network
1 current directorThe board mandates are listed under Board mandates elsewhere. The network lets you explore the same ties.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Timeline
21 events since 2015Board
Filings
Financial
Establishments
Address
201620182020202220242026
Deadline for the 2026 accounts: 30-04-2027
2026
Annual accounts 2025 filed PDFabbreviated format · 16 days before the deadline
2025
Equity above €500,000 equity €502,844 ▲11.9% With a profit in every financial year since 2016, equity grows to €502,844.
Registered in the Peppol Directory Reachable for e-invoices through 0208:0597740922
Annual accounts 2024 filed PDFabbreviated format · 19 days before the deadline
2024
Weakest financial year net €17,244 ▼81.1% The net result drops to €17,244, the lowest from 2016 to 2025. It recovers the following year.
Annual accounts 2023 filed PDFabbreviated format · 5 days before the deadline
- 100 shares
- Director resignation, VANDERSTEEN Zoë
- Director reappointment, VANDERSTEEN Zoë (director (not named in the articles))
- Registered office clause, Zuundallaan 22, 1600 Sint-Pieters-Leeuw
- Power of attorney, Lode Leemans
- The deed holds 5 more points.
2023
Annual accounts 2022 filed PDFabbreviated format · 37 days before the deadline
2022
Highest result from 2016 to 2025 net €97,686 ▲34.2% The net result of €97,686 is the highest of those years.
Annual accounts 2021 filed PDFabbreviated format · 1 day before the deadline
2021
Annual accounts 2020 filed PDFabbreviated format · on the deadline day
2020
Equity above €200,000 equity €210,428 ▲33.6% With a profit in every financial year since 2016, equity grows to €210,428.
Registered office moved within Sint-Pieters-LeeuwNew registered office: Zuundallaan 22, 1600 Sint-Pieters-Leeuw · Previous registered office: Drogenbosstraat 25 bus 3, 1600 Sint-Pieters-Leeuw · General meeting of 06-11-20182 points ▸
- General meeting, 06-11-2018
- Registered-office move, Zuundallaan 22, 1600 Sint-Pieters-Leeuw
Annual accounts 2019 filed PDFabbreviated format · 20 days before the deadline
2019
Equity above €150,000 equity €157,471 ▲40.2% With a profit in every financial year since 2016, equity grows to €157,471.
Annual accounts 2018 filed PDFabbreviated format · 28 days before the deadline
2018
Equity above €100,000 equity €112,279 ▲232% With a profit in every financial year since 2016, equity grows to €112,279.
Annual accounts 2017 filed PDFabbreviated format · 27 days before the deadline
2017
Annual accounts 2016 filed PDFabbreviated format · 30 days before the deadline
2015
Incorporation PDFpublished on 10-02-2015
First establishment Zuundallaan 22, Sint-Pieters-Leeuw
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Identity
- Enterprise number
- 0597.740.922
- VAT number
- BE 0597.740.922
- Peppol ID
- 0208:0597740922
- Other Peppol ID
- 9925:BE0597740922
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 06-02-2015
- Financial year
- ends on 30 September
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Friday of March at 19:00deed of 01-02-2024 (in Dutch)
- Peppol
- Reachable since 25-09-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- VDS PHARMA in Dutch
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 01-02-2024 (in Dutch)
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Vlaams Gewest”deed of 01-02-2024 (in Dutch)
Activities
NACEBEL 202564210
Activities of holding companies main activity
Codes under NACEBEL 2008
64200
Holdings main activity
70220
Business consulting
82990
Other business support services
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “Het verlenen van diensten en adviezen aan personen en bedrijven, in het algemeen met betrekking tot het bedrijfsbeheer, managementadvies…”deed of 01-02-2024 (in Dutch)
13 activities
- Het verlenen van diensten en adviezen aan personen en bedrijven, in het algemeen met betrekking tot het bedrijfsbeheer, managementadvies, opportuniteitsonderzoek, marketing, acquisitieonderzoek en al wat daarmede rechtstreeks of onrechtstreeks verband houdt.
- Het aanleggen, het oordeelkundig uitbouwen en beheren van een onroerend vermogen; alle verrichtingen met betrekking tot onroerende goederen en onroerende zakelijke rechten zoals de huurfinanciering van onroerende goederen aan derden, het aankopen, verkopen, ruilen, bouwen, verbouwen, onderhouden, verhuren, huren, verkavelen, prospecteren en uitbaten van onroerende goederen; de aan- en verkoop, huur en verhuur van roerende goederen, alsmede alle handelingen die rechtstreeks of onrechtstreeks met dit voorwerp in verband staan en die van aard zijn de opbrengst van de roerende en onroerende goederen te bevorderen, alsmede zich borg te stellen voor het goede verloop van verbintenissen door derde personen aangegaan die het genot zouden hebben van deze roerende en onroerende goederen. Het aanleggen, het oordeelkundig uitbouwen en beheren van een roerend patrimonium, alle verrichtingen met betrekking tot roerende goederen en rechten, van welke aard ook, zoals het verwerven door inschrijving of aankoop en het beheren van aandelen, obligaties, kasbons of andere roerende waarden, van welke vorm ook, van Belgische of buitenlandse, bestaande of nog op te richten rechtspersonen en ondernemingen.
- De vennootschap zal alle industriële, commerciële, financiële, roerende en onroerende handelingen mogen verrichten in rechtstreeks of onrechtstreeks verband met haar voorwerp, die van aard zijn de verwezenlijking ervan te vergemakkelijken of uit te breiden, en die daartoe noodzakelijk zijn, nuttig of zelfs alleen maar bevorderend.
- Het ontwikkelen, kopen, verkopen, in licentie nemen of geven van octrooien, knowhow en aanverwante immateriële duurzame activa.
- De lease, verhuur, sale & leaseback van intellectuele eigendom, vergunningen en vergelijkbare producten en alle roerende goederen in de meest brede zin van het woord, met uitzondering van auteursrecht.
- Het verlenen van administratieve prestaties en computerservices.
- De aan- en verkoop, in- en uitvoer, commissiehandel en vertegenwoordiging van om het even welke goederen, in 't kort tussenpersoon in de handel, e-commerce in de meeste uitgebreide zin en in al zijn vormen.
- Zij kan tevens rechtstreeks of onrechtstreeks belangen nemen, hetzij door deelneming, inbreng, fusie, financiële tussenkomst of elke andere wijze, in alle vennootschappen, ondernemingen, samenwerkingsverbanden, beroepsverenigingen of groeperingen, bestaande of op te richten, zowel in België als in het buitenland, die een gelijkaardig of verwant voorwerp nastreven of waarvan het voorwerp in innige samenhang met het hare staat of die van aard kunnen zijn de ontwikkeling van haar onderneming te begunstigen of een bron van afzetten te vormen.
- Zij kan optreden als bestuurder, directielid, beheerder of vereffenaar in andere vennootschappen; zij kan tevens borg staan voor derden, zowel aandeelhouders, zaakvoerders als loutere derden, evenals hun leningen, voorschotten en kredieten toestaan, met respect voor de wettelijke beperkingen.
- De vennootschap mag haar voorwerp verwezenlijken, zowel in het binnen- als in het buitenland, op alle wijzen die zij het meest geschikt zal achten.
- Het bouwen en exploiteren van één of meer snellaadstations voor elektrische voertuigen en het toestaan van exploitatierechten op deze snellaadstations aan derden ongeacht de rechtsfiguur waaronder deze exploitatierechten aan derden worden toegestaan.
- Het ontwerpen, fabriceren, im- en exporteren, de groot- en kleinhandel, het herstellen, het onderhouden, het huren en verhuren van snellaadstations en alle onderdelen en toebehoren daarbij.
- Aan- en verkoop, groot- en kleinhandel, distributie & aanmaken van alle vormen van groene energie.
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Zuundallaan 22 registered office 1600 Sint-Pieters-Leeuw | 06-02-2015 | 2.239.917.763 |
Buildings and parcels at the address
- Ground area
- 785 m²
- Buildings
- 181 m²
- Volume, LiDAR
- 853 m³
- Tallest building
- 7.0 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 23077C0033/00D000 | 785 m² | 1 · 181 m² | 7.0 m · 2 |